Mission, Abbvie Partner to Develop DUB Enzyme Inhibitors for Parkinson’s and Alzheimer’s

Mission Therapeutics and AbbVie have established a new partnership aimed at developing specific inhibitors targeting deubiquitylating enzymes, or DUBs, for the treatment of Alzheimer’s and Parkinson’s diseases. DUBs are a large family of important enzymes that regulate the protein degradation process, some of which are involved in the destruction of misfolded and potentially toxic proteins known to be

Deterioration of Nerve Cell Structure Not the Main Cause of Early Parkinson’s Symptoms, Mouse Study Suggests

Although the structure of dopaminergic neurons gradually deteriorates before cell death, these alterations do not seem to account for the subtle impairments seen during the early stages of Parkinson’s disease, a mouse study has found. The study, “Progressively Disrupted Somatodendritic Morphology in Dopamine Neurons in a Mouse Parkinson’s Model,” was published in Movement Disorders. Parkinson’s is

PF-360 Provides Some Benefits But Does Not Improve Dopaminergic Function, Mouse Study Shows

Treatment with PF-360, an investigational leucine-rich repeat kinase 2 (LRRK2) inhibitor, can efficiently decrease LRRK2’s phosphorylation levels, known to be elevated in Parkinson’s patients, in the brains of a mouse model of Parkinson’s disease, a preclinical study reports. However, despite some observed dose-dependent therapeutic effects, including gait improvement, no robust changes in dopaminergic function were observed. Results

CXCL12/CXCR4 Blood Levels Can Help Diagnose Inflammation Linked to Parkinson’s, Study Suggests

Measuring blood levels of the signaling molecule CXCL12 and its receptor CXCR4 may help identify active inflammation in Parkinson’s disease patients, a study suggests. The study, “CXCL12 and CXCR4 in the Peripheral Blood of Patients with Parkinson’s Disease,” was published in Neuroimmunomodulation. CXCL12 is a small protein called a chemokine that triggers immune cells to the

CDC Selects Parkinson’s as One of the First Diseases Included in New Database

Throughout the year, you’ve heard the Foundation talk about a new database at the Centers for Disease Control (CDC) to collect vital demographic information on people living with neurological diseases. Earlier this fall, Congress gave the CDC funds to implement this database, called the National Neurological Conditions Surveillance System (NNCSS). The CDC recently announced that Parkinson’s is

Study Outlines Risk Factors for Levodopa-induced Dyskinesia in Newly Diagnosed PD Patients

Severe motor, functional, and gait impairment; cumulative levodopa exposure; anxiety, and sex are among the risk factors for developing levodopa-induced dyskinesia (LID) in people newly diagnosed  with Parkinson’s disease, according to results from the Parkinson’s Progression Markers Initiative (PPMI). The research, “Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort,” was

Inhibiting USP13 Enzyme Can Help Destroy Toxic Alpha-Synuclein Clumps, Mouse Study Finds

Inhibiting an enzyme called USP13 may represent an attractive therapeutic target for Parkinson’s and other neurodegenerative diseases, preclinical data suggests. These findings also could hold important implications for a therapy currently being developed to treat Parkinson’s disease — nilotinib. The study, “Ubiquitin specific protease-13 independently regulates parkin ubiquitination and alpha-synuclein clearance in alpha-synucleinopathies,” was published in

Finding Hope for Today

Sometimes you can feel as if you’re at the end of your proverbial rope. You’re holding on as tight as you can, hoping the blisters on the palms of your hands won’t become totally unbearable and you let go. I was thinking about all that’s going on lately in the world: tsunamis, earthquakes, hurricanes, flooding,